Intralesional interferon alpha-2b therapy for Buschke-Loewenstein tumour

Acta Derm Venereol. 1994 Nov;74(6):457-9. doi: 10.2340/0001555574457459.

Abstract

A patient with a Buschke-Loewenstein tumour associated with human papillomavirus type 6/11 is reported. He was intralesionally treated with human recombinant alpha-2b interferon (9 x 10(6) IU/day) three times weekly. The tumour completely disappeared within 5 months of continuous treatment which was well tolerated. Sixteen months after completion of therapy the patient remains well and free of disease.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Condylomata Acuminata / pathology
  • Condylomata Acuminata / therapy*
  • Disease-Free Survival
  • Follow-Up Studies
  • Groin
  • Humans
  • Injections, Intralesional
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Male
  • Papillomaviridae*
  • Papillomavirus Infections / pathology
  • Papillomavirus Infections / therapy*
  • Recombinant Proteins
  • Remission Induction
  • Skin Diseases / pathology
  • Skin Diseases / therapy*
  • Tumor Virus Infections / pathology
  • Tumor Virus Infections / therapy*

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins